Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Update on Tozadenant Trial for Parkinson’s

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial A research study in humans that aims to test a new intervention – this could be a drug, surgery or therapy like exercise or diet guidelines – to make sure it is effective and safe..  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.


On 11/15/17, Acorda Therapeutics, Inc. announced that several people living with Parkinson's who participated in the Phase III trial for tozadenant experienced agranulocytosis — a severe drop in the number of white blood cells which fight infection — leading to cases of sepsis and five fatalities. Participants in the trial will now have blood cell count monitoring increased from monthly to weekly.  The study has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA).

Tozadenant is an oral adenosine A2a receptor antagonist currently in Phase III development as an adjunctive Supplemental or secondary. In the context of Parkinson's, adjunctive medications are used to enhance the effects of levodopa. treatment to levodopaThe medication most commonly given to control the movement symptoms of Parkinson’s, usually with carbidopa. It is converted in the brain into dopamine. in Parkinson’s disease patients to reduce OFF time When medication is not working well. Symptoms become more noticeable and movement becomes more difficult..

Statement from the Parkinson’s Foundation

Our thoughts are with the family members who lost a loved one enrolled in this trial. Their participation in clinical research will ultimately help make life better for the people diagnosed with Parkinson's in the future. 

The Parkinson’s Foundation remains confident that Acorda and the FDA will investigate this rare event. Clinical trials in Parkinson’s disease — from oral therapies to surgical treatments — have had a strong safety record and they are critical in testing the safety and efficacy of investigational therapies.

In order to discover new PD therapies, we rely on brave and altruistic people, like the ones in this trial, to participate in clinical research. The Parkinson’s Foundation remains committed to supporting clinical research through our global network of Centers of Excellence and Parkinson’s Advocates in Research.

If you would like more information about the benefits and risks of clinical trial participation, learn more here.  If you have questions or concerns, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636).

Thursday, November 16, 2017
Parkinson's Foundation Hosts National Forum for Women Living with Parkinson's Disease
Wednesday, November 7, 2018

MIAMI & NEW YORK — NOVEMBER 7, 2018 —The Parkinson’s Foundation hosted the first national forum for women with Parkinson’s disease (PD) on October 19 at Baylor College of Medicine, a Parkinson’s Foundation Center of Excellence, in Houston, TX.

Parkinson’s Foundation Announces Expansion of Community Grants Program to Address Unmet Community Needs
Thursday, November 1, 2018

NEW YORK & MIAMI — November 1, 2018 — The Parkinson’s Foundation is proud to announce that it is requesting applications for community grants to be awarded nationwide for health, wellness and education programs that address unmet needs in the Parkinson’s disease (PD) community. In 2019, the Parkinson’s Foundation will award $1.2 million in community grants.

Parkinson’s Foundation Hosts Free Bilingual Caregiver Summit
Tuesday, October 30, 2018

MIAMI AND NEW YORK—October 30, 2018—The Parkinson’s Foundation will host a Caregiver Summit – “Cumbre Para Cuidadores” – geared specifically toward caregivers of people living with Parkinson’s disease (PD).

Parkinson’s Foundation Adds James Monhart to its Board of Directors
Monday, October 29, 2018

NEW YORK & MIAMI, October 29, 2018—The Parkinson’s Foundation today announced the election of James F.T. Monhart to its board of directors.

Parkinson’s Foundation Earns 4-Star Rating from Charity Navigator
Monday, October 22, 2018

NEW YORK AND MIAMI—October 22, 2018—The Parkinson’s Foundation has achieved a 4-star rating from Charity Navigator, the nation's largest and most-utilized evaluator of charities.

The 4-star rating is the highest rating given only to nonprofit organizations that exceed industry standards and outperform peers, while demonstrating strong financial health and commitment to accountability and transparency.

Parkinson’s Foundation Awards New Nurse Faculty Grant to Four Nurses Specializing in Parkinson’s Care
Thursday, October 11, 2018

NEW YORK & MIAMI — October 11, 2018 — The Parkinson’s Foundation announced that it has awarded its first-ever Parkinson’s Foundation Nurse Faculty Award to four nurses, totaling $30,000. The nurses, all graduates of the Edmond J.

Update on NUPLAZID — FDA finds no new or unexpected safety risks
Friday, September 21, 2018

On September 20, 2018, the U.S.

Parkinson’s Foundation Extends Bilingual National Helpline Hours
Tuesday, September 18, 2018

NEW YORK & MIAMI — September 18, 2018 — The Parkinson’s Foundation announced today that its toll-free Helpline, 1-800-4PD-INFO, will extend its hours, answering calls in English and Spanish, to help make life better for people with Parkinson’s disease (PD) and their families.

Parkinson’s Foundation Hosts Allied Team Training for Parkinson’s in Atlanta
Tuesday, September 11, 2018

NEW YORK & MIAMI—September 11, 2018—The Parkinson’s Foundation today announced the location of its signature professional education program course, Allied Team Training for Parkinson’s, ATTP®, for health care professionals treating patients with Parkinson’s disease, in Atlanta.

Parkinson’s Foundation Increases Funding to $6.2 Million to Advance Parkinson’s Research
Tuesday, August 14, 2018

NEW YORK & MIAMI — August 14, 2018 — The Parkinson’s Foundation announced today an increased investment of $6.2 million across 53 research grants to support the work of promising scientists in the field of Parkinson's disease (PD) in 2018.

Pages

mail icon

Subscribe here to get the latest news on treatments, research and other updates.